• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Take a Look at Preclinical and Clinical Phase Compounds That Are Most Likely to Succeed in the Cancer Therapeutics Market and Become High-Revenue Therapeutics for Their Developers

Posted on: Tuesday, 5 December 2006, 09:01 CST

Research and Markets (http://www.researchandmarkets.com/reports/c46476) has announced the addition of "Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success" to their offering.

This is a unique and unrivalled 367-page report analysing the performance of numerous important early stage oncology drug candidates, assessing their market viability based on preclinical scientific studies and expert opinion. In the report, analysts decode the necessary parameters of market success for novel and next-generation drug targets. Through their diligent market research and academic insight, founded on years of experience of directing a preclinical research facility for the assessment of drug targets for solid tumours, the authors identify which oncology classes and products are most suited for regulatory approval and commercial success from those that may not fare as well in the global marketplace. The report represents an essential intelligence tool for deciphering capital risk and investment in oncology therapeutics whilst also enabling important decision-making with regard to research and development programmes and strategies, regulatory issues, and marketing challenges. Furthermore, market estimations for drug classes are provided revealing those preclinical and clinical phase compounds that are most likely to succeed in the market and become high-revenue therapeutics for their developers

In this Spectra Intelligence report the reader will be provided with a high-level expert analysis of the current challenging milieu for cancer research and drug development. Based on the review of recent preclinical and clinical data, top prospects for market success are identified through new oncology drug approaches and novel agents that are on-track for significant commercial prosperity.

Chapter 1 provides a comprehensive overview of tumour biology, oncogenetics, the mechanisms of neoplastic transformation and the role of various elements of malignancy as potential drug targets. The Chapter also discusses the current challenges to cancer research and drug development and reveals models of success for cancer therapies and in addition to the limitations of current therapeutic approaches.

Chapter 2 presents an overview of the novel tools of technology responsible for the vast expansion in the rate and novelty of pharmacological drug design in the treatment of cancer. Important themes covered in this chapter include rational drug design approaches, recombinant DNA technologies applied to drug discovery, and tumour-targeted approaches. Taken together, these therapeutic approaches and their associated technologies provide the core of current drug development trends and are the basis of future drug discovery and development. Each of these important drug discovery technologies is explored in detail, particularly as they relate to the development of new cancer medicines.

Cancer immunology is one of the most important areas of cancer biology as it impacts the genesis of cancer as well as many important therapeutic modalities. Chapter 3 provides an overview of our current state of understanding of the important immunological components of oncogenesis, particularly as they relate to the development of novel therapeutics for the treatment of many types of cancer. Of major importance is the monoclonal antibody technology that has emerged at the forefront of cancer therapeutic technologies and has produced such clinical successes as Herceptin and Avastin. In addition to a comprehensive review of the latest technologies and therapeutic advances in tumour immunotherapy, the chapter also provides an expert assessment of the development of preventive and genetically engineered therapeutic cancer vaccines.

Chapter 4 provides a comprehensive assessment of one of the most important areas of preclinical therapeutic cancer research - small molecule inhibitors, which target specific abnormal gene products and pathways in malignant cells. This exciting area of preclinical cancer research has produced one of the great therapeutic success stories of recent times, the introduction of Gleevec for the treatment of patients with chronic myeloid leukaemia. The success of this small molecule targeted therapeutic has ushered in a new era in the treatment of cancer and has turned a once fatal illness into a manageable disease. Most importantly, the drug's introduction represents not an isolated discovery, but rather a new paradigm for the development of targeted cancer therapeutics. The Chapter discusses in-depth these important advances and the development of the 'next generation' small molecule inhibitors and their promise in the treatment of many diverse forms of cancer.

Hormonal anticancer therapeutics are introduced in Chapter 5 as a further important class of drug to successfully treat cancer. The steroid superfamily of receptors is discussed in detail in regard to their utility as next generation drug targets. Selective oestrogen receptor modulators, aromatase inhibitors, and androgen receptors, for example, are critically discussed with regard to their roles as promising anticancer therapeutics.

Angiogenesis is a critical mechanism in the neoplastic pathway and is importantly associated with malignancy. Chapter 6 discusses the molecular characteristics of tumour vasculature and the role of the pro-angiogenic elements in tumour survival and metastases. The Chapter further analyses the potential pro-angiogenic molecules that hold great promise as druggable targets based on current preclinical research and early phase drug development data. Molecules of interest include angiogenin, canstatin, growth factors, and receptor tyrosine kinases. The chapter also provides an assessment of the challenges encountered in monoclonal antibody drug development and gene therapy approaches to cancer.

Chapter 7 provides a comprehensive analysis of preclinical prospects for haematopoetic cancers. It highlights some of the most important recent developments initiated by the successful introduction of Gleevec for the treatment of chronic myelogenous leukaemia. The dramatic clinical success afforded by this targeted small molecule therapeutic has become a paradigm for the development of targeted therapeutic approaches to the treatment of cancer. This Chapter explores the research and development of next generation targeted therapeutics that expand on the successes of Gleevec and include therapeutics that are currently in development for the treatment of refractory

Key topics covered:

- Preclinical Challenges in the Development of New Pharmacological Agents to Treat Cancer - Tools for Preclinicaldrug Development - Cancer Immunotherapy - Targeted Cancer Therapeutics: Smallmolecule Inhibitors In Preclinical Development - Hormonal Agents as Therapeutic Oncologytargets - Preclinical Angiogenic Cancer Targets - Preclinical Prospects for Haematopoetic Cancers - Preclinical Approaches to the Treatment of Solid Tumourmalignancies - Market Outlook for Themostpromising Anticancer Drugs Currently in Preclinical/Early Stage Clinical Development

For more information visit http://www.researchandmarkets.com/reports/c46476

Source: Business Wire

More News in this Category